A5016780118- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Cutaneous Melanoma Detection and Management
- BRCA gene mutations in cancer
- Esophageal and GI Pathology
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Frailty in Older Adults
- Vascular anomalies and interventions
- Gastrointestinal disorders and treatments
- Tracheal and airway disorders
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Muscle metabolism and nutrition
- Sarcoma Diagnosis and Treatment
- Musculoskeletal synovial abnormalities and treatments
- Lung Cancer Research Studies
- Renal and Vascular Pathologies
- DNA Repair Mechanisms
MedStar Franklin Square Medical Center
2011-2024
Weinberg Medical Physics (United States)
2023
NRG Oncology
2017-2023
MedStar Health
2020
Harry and Jeanette Weinberg Foundation
2012-2016
St. James's Hospital
2013
University of Maryland, Baltimore
2009
State University of New York
2007
Essex Cardiothoracic Centre
2002-2006
Roswell Park Comprehensive Cancer Center
2004
The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one the most frequent toxicities associated with taxane use for treatment early-stage breast cancer. We investigated impact three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes PN quality life (QOL).
Abstract Background The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)–based therapy. Seven-year results demonstrated a nonstatistically significant trend disease-free survival (DFS) favor ELT. We present 10-year outcome results. Methods In this double-blind, phase III trial, with stage I-IIIA hormone receptor–positive cancer, an...
PURPOSE The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2–negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. patient-reported outcome primary hypothesis was that OL-treated may experience greater fatigue during treatment. METHODS Data were collected before random assignment, at 6, 12, 18, 24...
Abstract Background The aim of this study was to investigate tracheal acid aspiration after oesophagectomy and determine whether it is influenced by nasogastric (NG) drainage. Methods Thirty-four patients undergoing were randomized one three methods NG drainage: a single-lumen tube with free drainage 4-hourly aspiration, sump-type on continuous suction drainage, or no tube. A pH probe used collect information for 48 h surgery. < 5·5 considered abnormal (normal 6·8–7·2). Total time...
Chemotherapeutic refractoriness of advanced cutaneous melanoma may be linked with melanoma-initiating cells, also known as stem cells. This study aimed to determine relative risk clonal dominance the CD133+ phenotype in tissues from patients different clinical outcomes that could applied early diagnosis, prognosis or disease monitoring. Significant overexpression CD133 (p<0.02) was observed by immunohistochemical staining recurrent versus those without recurrence. Relative analysis between...
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF dabrafenib BRAFV600 mutations. NRAS-mutated cell lines also sensitive to inhibition in vitro, tumors have shown partial response inhibitors. However, melanoma still has high recurrence rates due subpopulations, sometimes described as "melanoma initiating cells," resistant treatment. Since CD133 is a putative cancer stem marker different cancers, associated with decreased...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) are 2 cytokines with distinct mechanisms of action that complement one another in the adjuvant management melanoma. Forty-five patients high-risk melanoma were enrolled an open-label, single-arm, phase II clinical trial to examine safety, tolerability, effectiveness this combination. After potentially curative surgery, each patient received 12 months GM-CSF 125 μg/m2/d subcutaneously (SC) for 14 days followed...
Abstract Background: In the NSABP B-42 trial we aimed to determine whether 5 yrs of letrozole (L) v placebo (P) improves DFS in patients (pts) who have completed hormonal therapy (tx). 3966 postmenopausal pts with stage I-III, hormone-receptor+ BC, disease-free after an AI or tamoxifen (TAM) for ≤3 years → remainder yrs, were randomized L 2.5 mg P daily additional yrs. primary analyses beneficial effect extended tx did not reach statistical significance on survival (DFS). There was no...
Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess efficacy of seviprotimut-L, Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 reported here. Methods Patients...
Abstract Melanoma is an aggressive and lethal form of cancer, responsible for 9,710 deaths in the US every year, as indicated by Surveillance Epidemiology End Results (SEER) program. Although early stages are surgically treatable, advanced or metastatic most fatal, presumably due to resistance chemotherapy, radiation other therapies. Refractoriness melanoma self-renewal properties a subpopulation resistant cells, which may be same what have been termed “melanoma initiating cells” (MIC), many...
20027 Background: The results of various adjuvant trials in high-risk melanoma patients have demonstrated significant improvement survival, but the been inconsistent. GM-CSF and IL-2 are 2 cytokines with distinct mechanism action that synergistic, seemed logical to investigate as therapy. Methods: Forty-five enrolled this single-arm, open- labeled, IRB approved, phase II trial, evaluate safety, tolerability treatment effectiveness. After potentially curative surgery, each patient received...
Neuroendocrine neoplasms of the gallbladder occur infrequently, with diagnosis being incidental in most cases. We present a case an 81-year-old African American woman who initially presented acute suppurative cholecystitis, found on pathology to have moderately differentiated infiltrating adenocarcinoma. A partial hepatic resection periportal lymph node dissection was planned which subsequently aborted intraoperatively due presence diffuse carcinomatosis. Pathology cancerous lesions revealed...
Abstract Melanoma is an aggressive and lethal form of cancer with increasing incidence worldwide. In recent years, the FDA approved several promising treatments for malignant melanoma. However, treatment often fails due to survival regrowth drug-resistant cells. Studies by our lab others suggest that Initiating Cells (MIC), a CD133+ population forms xenograft tumors, may represent intermediate stage in acquisition stable drug resistance. This study aims determine effect CD133-expression...
Abstract Background: Melanoma is an aggressive and chemoresistant tumor.High risk melanoma minimally susceptible to current treatment strategies.These strategies have not yielded much appreciable survival benefits. It now clearly evident that cell-surface receptors play a pivotal role in transmitting extracellular signals intracellular effectors. Trophic factors exert profound influence on the tumor micro-environment through auto or paracrine signaling mechanisms course of coordinated...
9053 Background: Cutaneous melanoma cells express a variety of cytokines and growth factors (C/GF) as the tumor progresses. This study was undertaken to identify various C/GF at different stages disease with hope identifying prognostic factors. Methods: Immunohistochemical (IHC) studies were performed on 62 specimens parafinized human comprised 12 primaries, 10 local recurrences, 6 intransit, 15 regional lymph node 19 distant metastases. Staining for 17 using commercially available...
22197 Background: The non-surgical management of cutaneous melanoma remains blighted by poor and variable results. Cytokines growth factors (Factors) at the tumor site may act as autocrines paracrines that stimulate invasion. To identify some these Factors, we initiated 2 studies. Methods: 1. 7-day spent medium 25 cultured human cell lines were tested in triplicate ELISA assay for levels 24 Factors (14 cytokines 10 factors). In addition, recurrences three patients repeatedly biopsied...